{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:13:27Z","timestamp":1791213207443,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T00:00:00Z","timestamp":1224547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1038\/ncponc1251","type":"journal-article","created":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T11:51:46Z","timestamp":1224589906000},"page":"737-740","source":"Crossref","is-referenced-by-count":99,"title":["Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib"],"prefix":"10.1038","volume":"5","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,21]]},"reference":[{"key":"BFncponc1251_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/0016-5085(93)90849-8","volume":"104","author":"MA Weinstock","year":"1993","unstructured":"Weinstock MA (1993) Epidemiology and prognosis of anorectal melanoma. Gastroenterology 104: 174\u2013178","journal-title":"Gastroenterology"},{"key":"BFncponc1251_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/BF02140894","volume":"40","author":"C Thibault","year":"1997","unstructured":"Thibault C  et al. (1997) Anorectal melanoma: an incurable disease? Dis Colon Rectum 40: 661\u2013668","journal-title":"Dis Colon Rectum"},{"key":"BFncponc1251_CR3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1309\/EWK9-LUPR-6BC5-1GXV","volume":"118","author":"MV Sheffield","year":"2002","unstructured":"Sheffield MV  et al. (2002) Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol 118: 930\u2013936","journal-title":"Am J Clin Pathol"},{"key":"BFncponc1251_CR4","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2002.03.002","volume":"20","author":"MT Ballo","year":"2002","unstructured":"Ballo MT  et al. (2002) Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 20: 4555\u20134558","journal-title":"J Clin Oncol"},{"key":"BFncponc1251_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/cncr.20113","volume":"100","author":"KB Kim","year":"2004","unstructured":"Kim KB  et al. (2004) Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 100: 1478\u20131483","journal-title":"Cancer"},{"key":"BFncponc1251_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ijc.22681","volume":"121","author":"CR Antonescu","year":"2007","unstructured":"Antonescu CR  et al. (2007) L576 KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121: 257\u2013264","journal-title":"Int J Cancer"},{"key":"BFncponc1251_CR7","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","volume":"24","author":"JA Curtin","year":"2006","unstructured":"Curtin JA  et al. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340\u20134346","journal-title":"J Clin Oncol"},{"key":"BFncponc1251_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.humpath.2005.03.015","volume":"36","author":"C Willmore-Payne","year":"2005","unstructured":"Willmore-Payne C  et al.(2005) Human malignant melanoma: detection of BRAF-and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36: 486\u2013493","journal-title":"Hum Pathol"},{"key":"BFncponc1251_CR9","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1200\/JCO.2004.10.125","volume":"22","author":"PT Went","year":"2004","unstructured":"Went PT  et al. (2004) Prevalence of KIT expression in human tumors. J Clin Oncol 22: 4514\u20134522","journal-title":"J Clin Oncol"},{"key":"BFncponc1251_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1600-0463.2007.apm_587.x","volume":"115","author":"SE Steigen","year":"2007","unstructured":"Steigen SE  et al. (2007) Mutations in gastrointestinal stromal tumors\u2014a population-based study from Northern Norway. APMIS 115: 289\u2013298","journal-title":"APMIS"},{"key":"BFncponc1251_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/modpathol.2008.2","volume":"21","author":"J Lasota","year":"2008","unstructured":"Lasota J  et al. (2008) Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 21: 476\u2013484","journal-title":"Mod Pathol"},{"key":"BFncponc1251_CR12","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL  et al. (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23: 5357\u20135364","journal-title":"J Clin Oncol"},{"key":"BFncponc1251_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S  et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835\u2013844","journal-title":"Nat Rev Drug Discov"},{"key":"BFncponc1251_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"36","author":"H Davies","year":"2002","unstructured":"Davies H  et al. (2002) Mutations of the BRAF gene in human cancer. Nature 36: 949\u2013954","journal-title":"Nature"},{"key":"BFncponc1251_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.jid.5700026","volume":"126","author":"VK Goel","year":"2006","unstructured":"Goel VK  et al. (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Inest Dermatol 126: 154\u2013160","journal-title":"J Inest Dermatol"},{"key":"BFncponc1251_CR16","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-07-4123","volume":"14","author":"KT Flaherty","year":"2008","unstructured":"Flaherty KT  et al. (2008) A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14: 4836\u20134842","journal-title":"Clin Cancer Res"},{"key":"BFncponc1251_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR  et al. (2000) Randomized phase III study of temozolamide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158\u2013166","journal-title":"J Clin Oncol"},{"key":"BFncponc1251_CR18","unstructured":"Wellcome Trust Sanger Institute. Catalogue of somatic mutations in cancer site [\n                    http:\/\/www.sanger.ac.uk\/genetics\/CGP\/cosmic\/\n                    \n                  ] (accessed 24 July 2008)"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc1251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1251","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:54:10Z","timestamp":1684443250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc1251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,21]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["BFncponc1251"],"URL":"https:\/\/doi.org\/10.1038\/ncponc1251","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,21]]}}}